Faster And Cheaper: Similis Bio Aims To Enhance Biosimilar Development

Intends Deal With Blau Farmaceutica To Be ‘First Of Many’ Parallel Partnerships

30 Nov 2022

In the wake of Similis Bio’s first biosimilar partnership, the JSR Life Sciences unit’s head, John Gabrielson, talks to Generics Bulletin about the Similis Bio model and how the firm believes it can help bring biosimilars to market more rapidly and efficiently.

Jigsaw puzzle pieces partnership — Similis believes that through multiple partnerships it can help bring biosimilars to market more quickly and cost-effectively • Source: Shutterstock

Just months after JSR Life Sciences launched its Similis Bio business unit in May 2022, the early-stage biosimilars developer snagged its first major deal.

Similis Bio – which is focused on accelerating biosimilars development by pursuing biosimilar co-development agreements with multiple sponsors in parallel...